healthcare
Singapore's Aslan Pharma closes $43m Series C round
Singapore-based biotech developer Aslan Pharmaceuticals has closed its Series C round of funding at $43 million with additional capital from new investor MVP Capital Partners.
Taiwan ITRI, Japan’s Mitsubishi UFJ launch VC fund
Taiwan’s Industrial Technology Research Institute (ITRI) and Japan’s Mitsubishi UFJ Financial Group have jointly set up a second venture capital fund with a target of NT$2.5 billion ($75 million).
Rival bidder for China's iKang Healthcare hikes offer
A PE-backed consortium that includes Meinian Onehealth has increased its take-private offer for iKang Healthcare Group in response to a rival consortium led by the company’s founder bringing in a string of heavyweight investors.
Alibaba, OTPP join founder-led consortium bidding for iKang
Alibaba Group and Ontario Teachers’ Pension Plan (OTPP) have joined a consortium led by the founder and CEO of iKang Healthcare Group that is involved in a competitive battle to privatize the US-listed company.
PE-backed diagnostics player Thyrocare files for India IPO
Thyrocare Technologies, an Indian diagnostics company with several private equity backers, has filed for a domestic IPO.
Tsinghua Holdings reaches first close on China fund-of-funds
Redbud Capital, a VC fund-of-funds investment unit under Tsinghua Holdings, has reached a first close of RMB1 billion ($154 million) on its latest China-focused fund.
PE-backed Dr Lal PathLabs gains on India trading debut
Shares in Indian medical diagnostics service Dr. Lal PathLabs gained more than 50% on debut following the company's INR6.3 billion ($95 million) IPO.
WuXi Healthcare closes second Sino-US VC fund at $290m
WuXi Healthcare Ventures, a corporate venture arm owned by China-based WuXi PharmaTech, has closed its second early-stage healthcare fund at $290 million, exceeding the target of $200 million.
PE-backed group submits sweetened offer for China’s iKang
A PE-backed consortium that includes Meinian Onehealth has submitted a revised and improved proposal to acquire US-listed iKang Healthcare Group.
Goldstone, Legend lead $280m round for China CRO play
The Goldstone Investment-managed CITIC M&A Fund and Legend Capital have led a $280 million round of financing for Pharmaron, a Chinese contract research organization (CRO) company.
PE consortium completes take-private of China's WuXi PharmaTech
A consortium comprising the founder and CEO of WuXi PharmaTech and several PE investors has completed the privatization of the China-based provider of contract R&D services to global pharmaceutical companies.
LeapFrog gets $200m as OPIC commits to emerging markets GPs
The Overseas Private Investment Corporation (OPIC) has committed $200 million to LeapFrog Investments as part of a $1 billion financing drive for development-oriented funds in emerging markets.
Actis sells stake in Sri Lanka's Asiri Hospitals to TPG Growth
Actis has sold a 27.8% stake in Asiri Hospital Holdings (AHH), Sri Lanka’s largest private hospital group, to TPG Capital’s growth equity unit for LKR7.6 billion ($53.2 million).
AVCJ Awards 2015: Exit of the Year - Mid Cap: Bushu Pharmaceuticals
Tokio Marine aimed to awaken the ambition of Japan’s Bushu Pharmaceuticals and show how a good GP can turn companies around. A 6x return was its reward
Australian government unveils incentives for start-ups
The Australian government has introduced a range of measures to boost local innovation and entrepreneurship.
Singapore biotech firm Aslan Pharma raises $34m
Singapore-based biotech developer Aslan Pharmaceuticals has raised $34 million in a Series C round led by Accuron Technologies, a subsidiary of government-sponsored investment firm Temasek Holdings.
Australia's Archer agrees Healthe Care sale to China-based Luye
Archer Capital has agreed to sell Healthe Care, Australia’s third-largest private hospital group, to China-based Luye Medical Group, for $688 million. CITIC Private Equity is a shareholder in the company’s Hong Kong-listed affiliate, Luye Pharma.
China's iKang adopts poison pill following rival PE-backed buyout offer
IKang Healthcare Group – a US-listed Chinese company that is subject to competing PE-backed privatization proposals, one led by management and another involving an industry rival – plans a rights issue, or “poison pill” strategy, intended to thwart...
Goldman commits $20m in China biotech firm
Goldman Sachs has committed $20 million in a Series B round of funding to Ascletis, a Hangzhou-based biotechnology company.
J-Star owned medical insurer makes bolt-on acquisition
Nihon Hoken Service (NHS), a Tokyo-based insurance agency and insurance solicitation business bought by J-Star earlier this year, has completed the bolt-on acquisition of industry peer Sokisha Corporation.
Sequoia, Cathay join iKang take-private bid
Shenzhen-listed healthcare services provider Meinian Onehealth has teamed up with a group of investors – including Sequoia Capital and Cathay Capital Private Equity – to privatize its US-listed rival iKang Healthcare Group.
Highlight provides Series A for China’s eDoctor
Highlight Capital has led a Series A round of funding for eDoctor Healthcare Communications, a Chinese start-up specializing in pharmaceutical marketing solutions.
TPG, Carlyle complete exit from Australia's Healthscope
TPG Capital and The Carlyle Group have completed their exit from Australian hospital operator Healthscope, having privatized the company in 2010 and re-listed it last year.
OrbiMed exits India's Ecron Acunova for $17.4m
Indian life-science technology company Take Solutions has agreed to pay INR1.15 billion ($17.4 million) for Ecron Acunova (EA), providing an exit for healthcare-focused private equity firm OrbiMed Advisors.